Gasdermin‐ B ( GSDMB ) takes center stage in antibacterial defense, inflammatory diseases, and cancer
The FEBS Journal · 2024-07 · 291 (14) · 3060-3071
DOI: 10.1111/febs.17018 ↗At a glance
Übersichtsarbeit in The FEBS Journal, published online on 2023-12-06. Written by David Sarrio and 2 co-authors. Institution: Biochemistry Department, Instituto de Investigaciones Biomédicas "Alberto Sols" (IIBm-CISC), Conexión Cáncer (UAM-CSIC), Universidad Autónoma de Madr…. Major MEDLINE topics: Neoplasms, Inflammation, Pyroptosis. Cited 15 times so far (Crossref); 60 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Fundación Científica Asociación Española Contra el Cáncer, Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación, AEI.
Abstract (original language)
One of the hottest topics in biomedical research is to decipher the functional implications of the Gasdermin (GSDM) protein family in human pathologies. These proteins are the key effectors of a lytic and pro‐inflammatory cell death type termed pyroptosis (also known as “Gasdermin‐mediated programmed cell death”). However, ever‐growing evidence showed that GSDMs can play multiple and complex roles in a context‐dependent manner. In this sense, Gasdermin‐B (GSDMB; the only GSDM gene absent in mice and rats) has been implicated in antibacterial defense, numerous inflammatory pathologies (e.g., asthma, ulcerative colitis), and cancer, but both cell death‐dependent and ‐independent functions have been reported in these diseases, fueling the debate on whether GSDMB has genuine pyroptotic capacity. Recently, a series of seminal papers cast light on the GSDMB multitasking capacity by showing that different GSDMB transcriptional isoforms have distinct biological activities. Nonetheless, there are still obscure areas to be clarified on the precise functional involvement of GSDMB translated variants in physiological and pathological conditions. In this viewpoint, we critically discuss the most recent and exciting data on this topic and propose a series of relevant challenges that need to be overcome before GSDMB‐driven biomedical applications (as a biomarker of disease risk/progression/outcome or as specific therapeutic target) become a reality in clinical settings.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Biochemistry Department, Instituto de Investigaciones Biomédicas "Alberto Sols" (IIBm-CISC), Conexión Cáncer (UAM-CSIC), Universidad Autónoma de Madrid (UAM), Spain.
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain.
- Fundación MD Anderson Internacional, Madrid, Spain.
ORCID profiles: David Sarrio, Gema Moreno-Bueno
Funding
- Fundación Científica Asociación Española Contra el Cáncer
- Instituto de Salud Carlos III
- Ministerio de Ciencia e Innovación, AEI
- Ministerio de Ciencia e Innovación
Cite
APA
Sarrio, D., Colomo, S., & Moreno-Bueno, G. (2024). Gasdermin‐ B ( GSDMB ) takes center stage in antibacterial defense, inflammatory diseases, and cancer. The FEBS Journal, 291(14), 3060-3071. https://doi.org/10.1111/febs.17018
Vancouver
Sarrio D, Colomo S, Moreno-Bueno G. Gasdermin‐ B ( GSDMB ) takes center stage in antibacterial defense, inflammatory diseases, and cancer. The FEBS Journal. 2024;291(14):3060-3071. doi:10.1111/febs.17018
BibTeX
@article{Sarrio2024,
author = {Sarrio, David and Colomo, Sara and Moreno-Bueno, Gema},
title = {Gasdermin‐ B ( GSDMB ) takes center stage in antibacterial defense, inflammatory diseases, and cancer},
journal = {The FEBS Journal},
year = {2024},
volume = {291},
number = {14},
pages = {3060--3071},
doi = {10.1111/febs.17018}
}
EUVIMED